Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alivus Life SciencesNSE:ALIVUS +5.87%84 Return-on-Tangible-Asset is 16.20% as of Jun. 2026, which is 12% below its 10-year median of 18.49. GuruFocus rates NSE:ALIVUS with a GF Score™ of 84/100 and a GF Value™ of ₹1,021.07 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 1,009 Drug Manufacturers companies, Alivus Life Sciences ranks better than 89.1% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Alivus Life Sciences's annualizedNet Income for the quarter that ended in Jun. 2026 was ₹6,403 Mil. Alivus Life Sciences's average total tangible assets for the quarter that ended in Jun. 2026 was ₹39,530 Mil. Therefore, Alivus Life Sciences's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 16.20%.
The historical rank and industry rank for Alivus Life Sciences's Return-on-Tangible-Asset or its related term are showing as below:
NSE:ALIVUS'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 15.37 Med: 18.49 Max: 19.92
Current: 15.45
During the past 8 years, Alivus Life Sciences's highest Return-on-Tangible-Asset was 19.92%. The lowest was 15.37%. And the median was 18.49%.
NSE:ALIVUS's Return-on-Tangible-Asset is ranked better than 89.1% of 1009
companies
in the Drug Manufacturers industry
Industry Median: 3.13
vs NSE:ALIVUS: 15.45
Alivus Life Sciences (NSE:ALIVUS) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Alivus Life Sciences Return-on-Tangible-Asset Related Terms
Alivus Life Sciences Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Alivus Life Sciences's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alivus Life Sciences Return-on-Tangible-Asset Chart
NSE:ALIVUS vs ZTS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alivus Life Sciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alivus Life Sciences Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alivus Life Sciences's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Alivus Life Sciences's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 16.20% mean?
Alivus Life Sciences (NSE:ALIVUS) has a Return-on-Tangible-Asset of 16.20% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Alivus Life Sciences and its competitors. This is 12% below median its historical median of 18.49. Over the past decade, Alivus Life Sciences' Return-on-Tangible-Asset has ranged from 15.37 to 19.92. According to the industry distribution chart, Alivus Life Sciences ranks #110 out of 1009 companies in the Drug Manufacturers industry, placing it in the top 10.9%.
Is Alivus Life Sciences' Return-on-Tangible-Asset too high?
Alivus Life Sciences' current Return-on-Tangible-Asset of 16.20% is 12% below median its 10-year median of 18.49. Over the past 10 years, this metric has ranged from a low of 15.37 to a high of 19.92. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.13. Alivus Life Sciences' value of 16.20% is 417.6% above this industry median. Based on the distribution chart, Alivus Life Sciences ranks #110 out of 1009 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Alivus Life Sciences has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alivus Life Sciences' Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Alivus Life Sciences ranks #110 out of 1009 companies for Return-on-Tangible-Asset. This places Alivus Life Sciences in the top 11% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.13. Alivus Life Sciences' value of 16.20% is 417.6% above this benchmark. Historically, Alivus Life Sciences' own Return-on-Tangible-Asset has ranged from 15.37 to 19.92 over the past decade. While the company's 10-year median is 18.49 vs. the industry median of 3.13, Alivus Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.13, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alivus Life Sciences's current Return-on-Tangible-Asset of 16.20% is 417.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Alivus Life Sciences and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alivus Life Sciences's current Return-on-Tangible-Asset is 16.20%, which is 12% below median its own 10-year median of 18.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alivus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Alivus Life Sciences (NSE:ALIVUS) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,021.07, compared to a current price of ₹1,160.00 — trading 13.6% above its estimated fair value. The current Return-on-Tangible-Asset is 16.20%, which is 12% below median its 10-year median of 18.49 and 417.6% above the Drug Manufacturers industry median of 3.13. Alivus Life Sciences' overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Alivus Life Sciences (NSE:ALIVUS), the current Return-on-Tangible-Asset is 16.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alivus Life Sciences (NSE:ALIVUS) Overvalued in 2026?
Based on GuruFocus' analysis, Alivus Life Sciences stock appears to be overvalued.
The current stock price of ₹1,160.00 is trading 13.6% above its estimated GF Value™ of ₹1,021.07.
GuruFocus considers Alivus Life Sciences to be Modestly Overvalued.
Key valuation signals for NSE:ALIVUS:
Return-on-Tangible-Asset: 16.20% (12% below median its 10-year median of 18.49)
GF Value™: ₹1,021.07 vs. price of ₹1,160.00 (13.6% above fair value)
Industry Position: 417.6% above the Drug Manufacturers median (#110 of 1009)
No single metric tells the full story. See the NSE:ALIVUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alivus Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disorders, pain management, diabetes, urology, gastrointestinal disorders, and other therapeutic areas.
84GF Score
Get the complete analysis for NSE:ALIVUS
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ALIVUS has been successfully added to your 
